Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Expand Immunology Pipeline
11:14am, Monday, 22'nd Jun 2026
AbbVie (ABBV) shares rose by 6% following its agreement to acquire Apogee Therapeutics (APGE), which saw a remarkable 47% increase in its stock price. The acqu
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?
10:56am, Monday, 22'nd Jun 2026
ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.
Dow Jones still in the green but Nasdaq drops as hawkish Fed still looms
10:33am, Monday, 22'nd Jun 2026
2:30pm: Market movers Alphabet Inc (NASDAQ:GOOG) shares fell 5.5% after the company lost key AI researcher Noam Shazeer to OpenAI, fueling investor concerns...
Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE
10:30am, Monday, 22'nd Jun 2026
Micron (MU) is entering a new strategic partnership with Anthropic as Needham raises its price target on the AI memory stock. Credo Technology (CRDO) gets a new bull in Evercore ISI after it initiated
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
10:15am, Monday, 22'nd Jun 2026
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis,
AbbVie to acquire Apogee Therapeutics in $10.9B deal
10:07am, Monday, 22'nd Jun 2026
Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
09:15am, Monday, 22'nd Jun 2026
Read Also: AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients
5 Things to Know Before the Stock Market Opens
08:56am, Monday, 22'nd Jun 2026
Stocks are having a quiet morning Monday as investors come off a long holiday weekend with a close eye on peace talks between the U.S. and Iran; a second day of negotiations in Switzerland has reporte
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
07:42am, Monday, 22'nd Jun 2026
AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company's immunology and inflammation portfolio.
Breakfast News: AbbVie's $11 Billion Pounce
07:30am, Monday, 22'nd Jun 2026
AbbVie reportedly set to take over Apogee, Satya Nadella wants to upturn AI, and more
Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.
07:06am, Monday, 22'nd Jun 2026
AbbVie will acquire the clinical-stage biotech's pipeline of candidates for inflammatory and immunological diseases.
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
07:04am, Monday, 22'nd Jun 2026
AbbVie will acquire biotech Apogee Therapeutics for $10.9 billion in cash, they said on Monday, as the company builds its next-generation immunology pipeline.
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
07:00am, Monday, 22'nd Jun 2026
Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases A
Dow Jones opens higher but Nasdaq flat as hawkish Fed still looms
06:55am, Monday, 22'nd Jun 2026
10:50am: AbbVie snaps up Apogee for nearly $11B Abbvie Inc (NYSE:ABBV) (Abbvie Inc (NYSE:ABBV)) announced that it will acquire Apogee Therapeutics...
5 Dividend Stocks to Buy and Hold Forever
06:15am, Monday, 22'nd Jun 2026
Get rich slowly. How? Hold these stocks and reinvest the dividends they pay.
